WO2011161295A3 - Utilisation de composés anticalcineurine pour le traitement de pathologies associées à une néovascularisation oculaire - Google Patents

Utilisation de composés anticalcineurine pour le traitement de pathologies associées à une néovascularisation oculaire Download PDF

Info

Publication number
WO2011161295A3
WO2011161295A3 PCT/ES2011/070453 ES2011070453W WO2011161295A3 WO 2011161295 A3 WO2011161295 A3 WO 2011161295A3 ES 2011070453 W ES2011070453 W ES 2011070453W WO 2011161295 A3 WO2011161295 A3 WO 2011161295A3
Authority
WO
WIPO (PCT)
Prior art keywords
anticalcineurin
treatment
compounds
pathologies involving
ocular neovascularisation
Prior art date
Application number
PCT/ES2011/070453
Other languages
English (en)
Spanish (es)
Other versions
WO2011161295A2 (fr
Inventor
Juan Miguel Redondo Moya
Arántzazu ALFRANCA GONZÁLEZ
Original Assignee
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii filed Critical Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii
Publication of WO2011161295A2 publication Critical patent/WO2011161295A2/fr
Publication of WO2011161295A3 publication Critical patent/WO2011161295A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte à l'utilisation d'un composé à activité anticalcineurine pour la préparation d'un médicament destiné au traitement de pathologies associées à une néovascularisation, en particulier de celles associées à une néovascularisation oculaire.
PCT/ES2011/070453 2010-06-23 2011-06-22 Utilisation de composés anticalcineurine pour le traitement de pathologies associées à une néovascularisation oculaire WO2011161295A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201030972 2010-06-23
ES201030972 2010-06-23

Publications (2)

Publication Number Publication Date
WO2011161295A2 WO2011161295A2 (fr) 2011-12-29
WO2011161295A3 true WO2011161295A3 (fr) 2012-05-31

Family

ID=44677909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/070453 WO2011161295A2 (fr) 2010-06-23 2011-06-22 Utilisation de composés anticalcineurine pour le traitement de pathologies associées à une néovascularisation oculaire

Country Status (1)

Country Link
WO (1) WO2011161295A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092435A1 (en) * 2002-11-07 2004-05-13 Peyman Gholam A. Treatment of ocular disease
WO2008119500A1 (fr) * 2007-03-30 2008-10-09 Fovea Pharmaceuticals Sa Procédés pour traiter des maladies oculaires néovasculaires
US20090092665A1 (en) * 2007-10-08 2009-04-09 Lux Biosciences, Inc. OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR mTOR INHIBITORS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA2498191C (fr) 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Methode d'inhibition de la neovascularisation choroidienne

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092435A1 (en) * 2002-11-07 2004-05-13 Peyman Gholam A. Treatment of ocular disease
WO2008119500A1 (fr) * 2007-03-30 2008-10-09 Fovea Pharmaceuticals Sa Procédés pour traiter des maladies oculaires néovasculaires
US20090092665A1 (en) * 2007-10-08 2009-04-09 Lux Biosciences, Inc. OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR mTOR INHIBITORS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARIS SONMEZ ET AL: "Regression of severe corneal stromal neovascularization with topical cyclosporine 0.05% after penetrating keratoplasty for fungal corneal ulcer", INTERNATIONAL OPHTHALMOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 29, no. 2, 20 December 2007 (2007-12-20), pages 123 - 125, XP019677682, ISSN: 1573-2630 *
HERNANDEZ G L ET AL: "SELECTIVE INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-MEDIATEDANGIOGENESIS BY CYCLOSPORIN A: ROLES OF THE NUCLEAR FACTOR OF ACTIVATED T CELLS AND CYCLOOXYGENASE 2", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 193, no. 5, 5 March 2001 (2001-03-05), pages 607 - 620, XP002907209, ISSN: 0022-1007, DOI: 10.1084/JEM.193.5.607 *
KILMARTIN: "Cyclosporine-induced resolution of choroidal neovascularization associated with sympathetic ophthalmia", ARCHIVES OF OPHTHALMOLOGY, vol. 116, no. 2, 1 January 1998 (1998-01-01), pages 249, XP055012420, ISSN: 0003-9950, DOI: 10.1001/archopht.116.2.249 *
RUSNAK FRANK ET AL: "Calcineurin: form and function", PHYSIOLOGICAL REVIEWS, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 80, no. 4, 1 January 2000 (2000-01-01), pages 1483 - 1521, XP002182662, ISSN: 0031-9333 *

Also Published As

Publication number Publication date
WO2011161295A2 (fr) 2011-12-29

Similar Documents

Publication Publication Date Title
MY170713A (en) Treatment protocol of diabetes type 2
HK1197400A1 (zh) 治療 的化合物
ZA201403795B (en) Formulations for the treatment of diabetes
WO2012117000A8 (fr) 3-aminopyridines en tant qu'agonistes de gpbar1
AP3589A (en) A novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes
JO2939B1 (en) Tetrahydro-pyrido-pyrimidine derivatives
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
CA2873723A1 (fr) Inhibiteurs pyrrolopyrimidone et pyrrolopyridone de la tankyrase
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
WO2012104823A3 (fr) Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
IL225452A0 (en) Using mirnas for the diagnosis, prevention, treatment and monitoring of diseases involving macroautophagy abnormalities
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
WO2011000945A3 (fr) Aminoalcamides pour une utilisation dans le traitement de maladies inflammatoires, dégénératives ou démyélinisantes du système nerveux central
WO2011161295A3 (fr) Utilisation de composés anticalcineurine pour le traitement de pathologies associées à une néovascularisation oculaire
WO2014096300A3 (fr) Composés antibactériens
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
MX2011011180A (es) Compuestos que tienen efecto fisiologico.
GB201009091D0 (en) Compounds for the treatment of clostridium difficile-associated disease
GB201009094D0 (en) Compounds for the treatment of closridium difficile-associated disease
WO2014147578A3 (fr) Composés antibactériens contre des bactéries résistantes aux médicaments
GB201106970D0 (en) Compounds for the treatment of clostridium difficile-associated disease
GB201106972D0 (en) Compounds for the treatment of clostridium difficile-associated disease
AU2010901601A0 (en) Compound for the treatment of respiratory condition or disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11761096

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11761096

Country of ref document: EP

Kind code of ref document: A2